Skip to main content
Erschienen in: Journal of Inflammation 1/2016

Open Access 01.12.2016 | Short report

Mycobacterium leprae alters classical activation of human monocytes in vitro

verfasst von: Dorothy Fallows, Blas Peixoto, Gilla Kaplan, Claudia Manca

Erschienen in: Journal of Inflammation | Ausgabe 1/2016

Abstract

Background

Macrophages play a central role in the pathogenesis of leprosy, caused by Mycobacterium leprae. The polarized clinical presentations in leprosy are associated with differential immune activation. In tuberculoid leprosy, macrophages show a classical activation phenotype (M1), while macrophages in lepromatous disease display characteristics of alternative activation (M2). Bacille Calmette-Guérin (BCG) vaccination, which protects against leprosy, can promote sustained changes in monocyte response to unrelated pathogens and may preferentially direct monocytes towards an M1 protective phenotype. We previously reported that M. leprae can dampen the response of naïve human monocytes to a strong inducer of pro-inflammatory cytokines, such as BCG. Here, we investigated the ability of the pathogen to alter the direction of macrophage polarization and the impact of BCG vaccination on the monocyte response to M. leprae.

Findings

We show that in vitro exposure of monocytes from healthy donors to M. leprae interferes with subsequent M1 polarization, indicated by lower levels of M1-associated cytokine/chemokines released and reduced expression of M1 cell surface markers. Exposure to M. leprae phenolic glycolipid (PGL) 1, instead of whole bacteria, demonstrated a similar effect on M1 cytokine/chemokine release. In addition, we found that monocytes from 10-week old BCG-vaccinated infants released higher levels of the pro-inflammatory cytokines TNF-α and IL-1β in response to M. leprae compared to those from unvaccinated infants.

Conclusion

Exposure to M. leprae has an inhibitory effect on M1 macrophage polarization, likely mediated through PGL-1. By directing monocyte/macrophages preferentially towards M1 activation, BCG vaccination may render the cells more refractory to the inhibitory effects of subsequent M. leprae infection.
Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CM, DF, GK designed the study, interpreted the data and drafted the manuscript. CM, BP performed the experiments, and data analysis. All authors have read and approved the final manuscript.
Abkürzungen
BCG
Bacille Calmette-Guérin
PGL-1
Phenolic glycolipid 1
PBMC
Peripheral blood mononuclear cells
M1
Classical macrophage activation
M2
Alternative macrophage activation
TNF-α
Tumor necrosis factor alpha
IL-1β
Interleukin 1 beta
IL-12p70
Interleukin 12p70
IL-6
Interleukin 6
MCP-1
Monocyte chemotactic protein 1
IP-10
Interferon gamma-inducible protein 10
Rantes
Regulated on activation, normal T cell expressed and secreted
MIP-1α
Macrophage inflammatory protein 1 alpha
MIP-1β
Macrophage inflammatory protein 1 beta
IFN-γ
Interferon gamma
MOI
Multiplicity of infection
CCR7
C-C chemokine receptor type 7
HLA-DR
Human leukocyte antigen - antigen D related
CD40
Cluster of differentiation 40
CD80
Cluster of differentiation 80

Background

Macrophages play a central role in the pathogenesis of leprosy, a chronic debilitating disease caused by Mycobacterium leprae. Monocyte/macrophages show a dynamic plasticity, allowing them to respond to environmental stimuli by presenting a classical (M1) or alternative (M2) activation state [1]. M1-activated macrophages release high levels of pro-inflammatory cytokines with enhanced microbicidal activity; M2 macrophages produce inhibitory cytokines and are less responsive to stimuli [2, 3]. Leprosy presents as a spectrum of clinical manifestations, associated with differential immune activation. While tuberculoid leprosy shows robust cell-mediated immunity with predominantly M1-activated macrophages, lepromatous disease is characterized by strong humoral immunity and macrophages show an M2 phenotype [4, 5].
Bacille Calmette-Guérin (BCG) vaccination protects against leprosy and is associated with reduced burden of unrelated diseases, suggesting non-specific protection that may involve shaping innate immunity [68]. BCG vaccination has been shown to induce sustained changes in the phenotype of circulating monocytes, with greater pro-inflammatory cytokine production [9]. Moreover, ex vivo stimulation of peripheral blood mononuclear cells (PBMC) from 10-week old infants vaccinated at birth with BCG, revealed a gene expression signature similar to an M1 macrophage profile with down-regulation of M2-associated genes [10].
We previously reported that stimulation of naïve monocytes from healthy donors with M. leprae alone, or M. leprae followed by BCG, induced the release of cytokine/chemokines that are associated with negative regulation of inflammation [11]. M. leprae itself was a poor inducer of the pro-inflammatory cytokine TNF-α, consistent with other reports [12]. However, when naïve monocytes were first stimulated by BCG and then exposed to M. leprae, the cells produced a pro-inflammatory cytokine profile matching that of BCG alone [11]. Here, we investigated the ability of M. leprae to interfere with M1 maturation of monocyte induced by exposure to IFN-γ and M2 maturation induced by exposure to IL4/IL13 in vitro. We also tested whether BCG vaccination, by favoring an M1 phenotype, may render the cells resistant to the inhibitory effects of M. leprae.

Methods

Reagents

Mycobacterium leprae Thai-53 from the National Hansen’s Disease Programs Laboratory Research, Louisiana State University, Baton Rouge (American Leprosy Missions and the Society of St. Lazarus) [1315] and BCG from Trudeau Institute (Mycobacterial Culture Collection No. 1011) were prepared as described [11]. Purified M. leprae PGL-1, obtained through the NIH Biodefense and Emerging Infections Research Resources Repository NIAID, NIH: NR-19342, was used as described [16]. Peripheral blood mononuclear cells (PBMCs) from 10-week old infants unvaccinated (N = 18) or BCG-vaccinated at birth (N = 20) were provided by Dr. Willem Hanekom, University of Cape Town, South Africa.
These studies were approved by the Institutional Review Boards of Rutgers University and the University of Cape Town (Pro2012001418, Pro0120110233).

Monocyte preparation/stimulation

PBMCs were isolated from buffy coat (New Jersey Blood Center) of healthy donors; monocytes were purified using anti-CD14 antibody-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA) and allowed to adhere before treatment [11]. For M1 polarization, monocytes were exposed to IFN-γ (10 ng/ml) for 24 h, then stimulated with LPS (100 ng/ml) for 19 h [3, 17]. M2 polarization was achieved by treatment with IL-4/IL-13(10 ng/ml each) for 24 h [18, 19]. To determine the impact of M. leprae, cells were exposed to M. leprae at multiplicity of infection (MOI) 5:1 or 20:1 (bacilli:cells) for 5 h prior to IFN-γ priming (M1) or IL-4/IL-13 treatment (M2). Cell viability was confirmed by trypan blue exclusion (Life Technologies, CA). Controls included: M1 or M2 polarization alone, M. leprae-stimulation alone, and unstimulated/untreated cells.
Monocytes were isolated from infant PBMCs by adherence [11], plated in 96-well plates (1x105 cells/well) in RPMI 1640/20 % human serum, and exposed to M. leprae (MOI 5:1) or culture medium alone.

Analysis

Cell supernatants were removed after 48 h (M1) or 24 h (M2) and probed using a multiplex human cytokine/chemokine panel (Bio-Rad, Hercules, CA) according to manufacturer’s instructions. Data/statistical analysis were done as described [16]. Cells were detached with EDTA (20 mM in PBS), washed with PBS, incubated with fluorescently-labeled antibodies against: CCR7, HLA-DR, CD80, CD86, and CD40 (BD Bioscience) (M1) or CD23 (M2), and analyzed on a FACSCalibur (BD Biosciences) using CellQuest (BD Biosciences) and FlowJo (Tree Star) software. Greater than 2,000,000 events per sample were analyzed.

Results and Discussion

M1 polarized monocytes (positive control) released high levels of TNF-α (mean 123.4 ± 17.0 ng/ml), IL-6 (152.1 ± 175.3 ng/ml), IL-1β (0.3 ± 0.07 ng/ml), IL-12p70 (2.1 ± 0.8 ng/ml), MCP-1 (6.2 ± 2 ng/ml), IP-10 (121 ± 18.9), Rantes (11.6 ± 2.3 ng/ml), MIP-1α (22.5 ± 3.2 ng/ml) and MIP-1β (88.7 ± 26.7 ng/ml) compared to unstimulated/untreated cells. Exposure of cells to M. leprae (MOI 5:1) prior to M1 polarization significantly reduced levels of IL-6, IL-1β and IL-12p70 by 19 % ± 27, 47 % ± 25, and 46 % ± 20, respectively, compared to M1 controls (Fig. 1a). Pre-stimulation with M. leprae at higher MOI (20:1) led to further reduction; IL-6, IL-1β and IL-12p70 were reduced by 36 % ± 32, 62 % ± 28 and 60 % ± 25, respectively. TNF-α was also significantly lowered by 22.2 % ±5.0 in response to M. leprae pre-stimulation, but only at higher MOI. In contrast, MCP-1 and IP-10 levels were significantly increased (P ≤ 0.0001 and P ≤ 0.05, respectively) by M. leprae (MOI 5:1) pre-stimulation compared to M1 controls (Fig. 1b). While M. leprae at the higher MOI further increased levels of MCP-1 (P ≤ 0.001), IP-10 levels were not significantly different at the two MOIs (Fig. 1b). No consistent differences were seen in Rantes, MIP-1α and MIP-1β (data not shown), suggesting that the impact of M. leprae on M1 polarization was selective. The inhibitory effect of M. leprae on M1 polarization observed here may involve interference with IFN-γ signaling, as described in monocyte/macrophages exposed to Mycobacterium tuberculosis and in M. leprae-infected nude mice [2022]. When monocytes were pre-exposed to PGL-1, instead of whole bacteria, the results were even more dramatic (Fig. 1c). M1 polarized controls released high levels of TNF-α (mean 24,243 ± 7,182 pg/ml), IL-6 (50,348 ± 8913 pg/ml) and IL-1β (75.5 ± 23.2 pg/ml), which were significantly reduced by PGL-1 pre-exposure (TNF-α: 6.7 ± 3.9 pg/ml; IL-6:18.3 ± 3.9 pg/ml; IL-1β:12.6 ± 2.0 pg/ml). PGL-1 alone induced cytokine levels comparable to unstimulated/untreated controls. These results support previous reports that PGL-1 is an important determinant in M. leprae-monocyte interactions [16, 23, 24].
M1 polarization also resulted in significantly increased percentages of cells expressing the surface markers CCR7 and CD40, relative to unstimulated/untreated controls. When monocytes were pre-exposed to M. leprae at low MOI, the percentages of CCR7+ (P ≤ 0.001) and CD40+ (P ≤ 0.05) cells were reduced compared to M1 polarization alone (Fig. 2). Pre-stimulation with M. leprae at higher MOI did not result in further reduction (data not shown). HLA-DR+, CD80+ and CD86+ M1 cell percentages were unaffected by M. leprae pre-stimulation. The mean fluorescence intensities (MFI) of CCR7, CD40 and CD80 in M1 cells were also significantly reduced by M. leprae pre-exposure (Table 1). M. leprae alone was comparable to unstimulated/untreated controls.
Table 1
M. leprae effect on the MFI of M1 surface markers
 
Phenotypic markers
 
CCR7
CD40
CD80
M1 cells
248.0 ± 31.7
51.6 ± 6.3
765.0 ± 64.2
Lep5 (5 h)/M1
167.1** ± 22.6
40.4* ± 6.5
681.9 ± 77.6
Lep20 (5 h)/M1
152.2* ± 7.9
46.3 ± 7.8
591.0* ± 70.1
Unstimulated cells
44.3** ± 1.7
6.5*** ± 0.3
16.6*** ± 2.8
 Lep5
48.4** ± 1.6
7.8*** ± 0.3
20.3*** ± 2.8
 Lep20
49.3** ± 1.4
7.8** ± 0.4
25.3*** ± 3.3
The values represent the mean MFI ± Sem of 4–7 independent experiments (independent donors) for each condition. The statistical significance is shown as compared to the M1 cells. Lep5 (M. leprae MOI 5:1); Lep20 (M. leprae MOI 20:1).*P ≤ 0.05; **P ≤ 0.001 and ***P ≤ 0.0001
In contrast, the impact of M. leprae on expression of M2 macrophage markers was minimal. Pre-stimulation with M. leprae increased the MFI of CD23 (295 ± 116 and 388.5 ± 153 at MOI 5:1 and 20:1, respectively) over M2 polarization alone (242.7 ± 108), with low levels produced by unstimulated/untreated cells (24.9 ± 12.3), and had no effect on IL-1Ra and IL-10 (data not shown). Thus, the effect of M. leprae on monocytes is primarily due to inhibition of M1 activation and does not appear to significantly affect M2 polarization.
Finally, we compared the effect of M. leprae on monocytes from 10-week old unvaccinated or BCG-vaccinated infants (Fig. 3). Levels of TNF-α and IL-1β released in response to M. leprae were significantly higher in monocytes from vaccinated infants than those from unvaccinated infants, while IL-6 and MCP-1 showed trends towards higher levels in vaccinated versus unvaccinated infants. These results demonstrate that in vivo activation of monocytes due to BCG vaccination may render the cells refractory to the inhibitory effects of M. leprae.

Conclusion

Exposure to M. leprae can alter the functional capacity of monocytes, which may diminish the efficacy of the host response to subsequent stimuli. Our results support increasing evidence suggesting that the innate immune response may be shaped by prior history of exposure, which could also explain the protection afforded by BCG vaccination against M. leprae and other unrelated pathogens.

Acknowledgements

This work was supported by grants from NIH (R21AI101349) and from the New York Community Trust awarded to CM. The authors would like to thank Dr. Guibin Yang for technical advice. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CM, DF, GK designed the study, interpreted the data and drafted the manuscript. CM, BP performed the experiments, and data analysis. All authors have read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Mege JL, Mehraj V, Capo C. Macrophage polarization and bacterial infections. Curr Opin Infect Dis. 2011;24:230–4.CrossRefPubMed Mege JL, Mehraj V, Capo C. Macrophage polarization and bacterial infections. Curr Opin Infect Dis. 2011;24:230–4.CrossRefPubMed
3.
4.
Zurück zum Zitat Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol. 2008;181:3733–9.CrossRefPubMed Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol. 2008;181:3733–9.CrossRefPubMed
5.
Zurück zum Zitat Montoya D, Cruz D, Teles RM, Lee DJ, Ochoa MT, Krutzik SR, Chun R, Schenk M, Zhang X, Ferguson BG, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe. 2009;6:343–53. Montoya D, Cruz D, Teles RM, Lee DJ, Ochoa MT, Krutzik SR, Chun R, Schenk M, Zhang X, Ferguson BG, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe. 2009;6:343–53.
6.
Zurück zum Zitat Sarno EN, Duppre NC, Sales AM, Hacker MA, Nery JA, de Matos HJ. Leprosy exposure, infection and disease: a 25-year surveillance study of leprosy patient contacts. Mem Inst Oswaldo Cruz. 2012;107:1054–9.CrossRefPubMed Sarno EN, Duppre NC, Sales AM, Hacker MA, Nery JA, de Matos HJ. Leprosy exposure, infection and disease: a 25-year surveillance study of leprosy patient contacts. Mem Inst Oswaldo Cruz. 2012;107:1054–9.CrossRefPubMed
8.
Zurück zum Zitat Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol. 2015;98:347–56.CrossRefPubMed Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol. 2015;98:347–56.CrossRefPubMed
9.
Zurück zum Zitat Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109:17537–42.CrossRefPubMedPubMedCentral Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109:17537–42.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC medical genomics. 2009;2:10.CrossRefPubMedPubMedCentral Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC medical genomics. 2009;2:10.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, Manca C. Mycobacterium leprae actively modulates the cytokine response in naive human monocytes. Infect Immun. 2010;78:293–300.CrossRefPubMedPubMedCentral Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, Manca C. Mycobacterium leprae actively modulates the cytokine response in naive human monocytes. Infect Immun. 2010;78:293–300.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Oliveira MM, Charlab R, Pessolani MC. Mycobacterium bovis BCG but not Mycobacterium leprae induces TNF-alpha secretion in human monocytic THP-1 cells. Mem Inst Oswaldo Cruz. 2001;96:973–8.CrossRefPubMed Oliveira MM, Charlab R, Pessolani MC. Mycobacterium bovis BCG but not Mycobacterium leprae induces TNF-alpha secretion in human monocytic THP-1 cells. Mem Inst Oswaldo Cruz. 2001;96:973–8.CrossRefPubMed
13.
Zurück zum Zitat Lahiri R, Randhawa B, Krahenbuhl J. Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J Med Microbiol. 2005;54:235–42.CrossRefPubMed Lahiri R, Randhawa B, Krahenbuhl J. Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J Med Microbiol. 2005;54:235–42.CrossRefPubMed
14.
Zurück zum Zitat Shepard CC, McRae DH. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968;36:78–82.PubMed Shepard CC, McRae DH. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968;36:78–82.PubMed
15.
Zurück zum Zitat Adams LB, Soileau NA, Battista JR, Krahenbuhl JL. Inhibition of metabolism and growth of Mycobacterium leprae by gamma irradiation. Int J Lepr Other Mycobact Dis. 2000;68:1–10.PubMed Adams LB, Soileau NA, Battista JR, Krahenbuhl JL. Inhibition of metabolism and growth of Mycobacterium leprae by gamma irradiation. Int J Lepr Other Mycobact Dis. 2000;68:1–10.PubMed
16.
Zurück zum Zitat Manca C, Peixoto B, Malaga W, Guilhot C, Kaplan G. Modulation of the cytokine response in human monocytes by mycobacterium leprae phenolic glycolipid-1. J Interferon Cytokine Res. 2012;32:27–33.CrossRefPubMedPubMedCentral Manca C, Peixoto B, Malaga W, Guilhot C, Kaplan G. Modulation of the cytokine response in human monocytes by mycobacterium leprae phenolic glycolipid-1. J Interferon Cytokine Res. 2012;32:27–33.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, Stupin Polancec D, Belamaric D, Parnham MJ, Erakovic Haber V. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol. 2012;165:1348–60.CrossRefPubMedPubMedCentral Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, Stupin Polancec D, Belamaric D, Parnham MJ, Erakovic Haber V. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol. 2012;165:1348–60.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6:137–43. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6:137–43.
19.
Zurück zum Zitat Meyer M, Huaux F, Gavilanes X, van den Brule S, Lebecque P, Lo Re S, Lison D, Scholte B, Wallemacq P, Leal T. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol. 2009;41:590–602.CrossRefPubMed Meyer M, Huaux F, Gavilanes X, van den Brule S, Lebecque P, Lo Re S, Lison D, Scholte B, Wallemacq P, Leal T. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol. 2009;41:590–602.CrossRefPubMed
20.
Zurück zum Zitat Pai RK, Pennini ME, Tobian AA, Canaday DH, Boom WH, Harding CV. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect Immun. 2004;72:6603–14.CrossRefPubMedPubMedCentral Pai RK, Pennini ME, Tobian AA, Canaday DH, Boom WH, Harding CV. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect Immun. 2004;72:6603–14.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR, Rubin EJ, Ernst JD. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol. 2004;172:6272–80.CrossRefPubMed Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR, Rubin EJ, Ernst JD. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol. 2004;172:6272–80.CrossRefPubMed
22.
Zurück zum Zitat Sibley LD, Hunter SW, Brennan PJ, Krahenbuhl JL. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun. 1988;56:1232–6.PubMedPubMedCentral Sibley LD, Hunter SW, Brennan PJ, Krahenbuhl JL. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun. 1988;56:1232–6.PubMedPubMedCentral
23.
Zurück zum Zitat Dhungel S, Ranjit C, Sapkota BR, Macdonald M. Role of PGL-I of M. leprae in TNF-alpha production by in vitro whole blood assay. Nepal Med Coll J. 2008;10:1–3.PubMed Dhungel S, Ranjit C, Sapkota BR, Macdonald M. Role of PGL-I of M. leprae in TNF-alpha production by in vitro whole blood assay. Nepal Med Coll J. 2008;10:1–3.PubMed
24.
Zurück zum Zitat Liu PT, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, Ferguson B, Mehta MD, Vazirnia A, Rea TH, Sarno EN, et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012;18:267–73.CrossRefPubMedPubMedCentral Liu PT, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, Ferguson B, Mehta MD, Vazirnia A, Rea TH, Sarno EN, et al. MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012;18:267–73.CrossRefPubMedPubMedCentral
Metadaten
Titel
Mycobacterium leprae alters classical activation of human monocytes in vitro
verfasst von
Dorothy Fallows
Blas Peixoto
Gilla Kaplan
Claudia Manca
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
Journal of Inflammation / Ausgabe 1/2016
Elektronische ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-016-0117-4

Weitere Artikel der Ausgabe 1/2016

Journal of Inflammation 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.